Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to establish Phase 2 of the U.S.-South Africa Program for Collaborative Biomedical Research.  Research areas supported under this program include: sexually transmitted infections; parasitic infections; arboviruses and emerging/re-emerging viral pathogens; and vector biology and control. The intent of this FOA is to foster, stimulate, and/or expand basic, translational, behavioral and applied research that will advance scientific discovery and engage U.S. and South African scientists working collaboratively in the areas of infectious disease research.  Proposed research should reflect the highest possible scientific standards, as well as shared interests, international and local public health needs and priorities, and involve mutually advantageous collaborations among institutions, including participating communities and other partners.  U.S. and South African investigators working in partnership will prepare and submit a single joint application.  Applications must include at least one PD/PI affiliated with the U.S. institution and a South African PD/PI from an eligible institution from South Africa.

The purpose of this Funding Opportunity Announcement (FOA) is to support the planning and development of translational research programs focused upon cancer health disparities research. The P20 grants supported by this FOA are expected to expand into comprehensive translational research programs focused upon cancer health disparities and ultimately compete for P50 awards under the umbrella of the National Cancer Institute (NCI) "Specialized Programs of Research Excellence (SPOREs)". Each P20 Program proposed must include the following components: Research Program (at least two translational research projects are required); Administrative Core; Shared Resource Facility (Biospecimen/Pathology Core is required); and Developmental Research Program. The research supported through the P20 Program must be translational in nature and must focus upon knowledge of human biology with a translational human endpoint proposed. The proposed research theme for the P20 Program must be focused on addressing disparities in cancer incidence, prevalence, mortality, survivorship, and/or burden of cancer, or related health conditions, that are well documented among racial/ethnic minority populations. Projects may focus on a wide range of research areas including prevention, early detection, diagnosis, treatment, epidemiology and/or cancer control, and are expected to have clear translational potential to advance research findings to applications relevant for clinical practice and/or healthcare settings.

The purpose of this Funding Opportunity Announcement (FOA) is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation.

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is aimed at revolutionizing neuroscience through development and application of innovative technologies to map neural circuits, monitor and modulate their activity, and understand how they contribute to thoughts, sensations, emotions and behavior. NIH has issued a variety of Funding Opportunity Announcements (FOAs) that will support projects that apply technologies to understand neural circuit function in the context of specific circuits, resulting in a diverse portfolio of research into the fundamental biology of nervous system function. The purpose of this announcement is to notify the research community that NIH welcomes BRAIN Initiative applications targeting central nervous system nociceptive and pain circuits, as appropriate to the goals and requirements of specific BRAIN Initiative FOAs. Pain conditions represent an important public health problem and NIH continues to support research into pain pathologies through normal Institute and Center appropriations. However, pain and nociception are also components of normal nervous system function, and the BRAIN Initiative is committed to understanding pain circuits along with brain circuits underlying other sensory, motor, cognitive and emotional functions. It is expected that the unique opportunities of the BRAIN Initiative will enable production of detailed maps of pain circuits, and the adoption of powerful new tools for monitoring and modulating pain circuit activity, leading to significant advances in the understanding of pain and nociception. For a list of past and open BRAIN Initiative FOAs, see https://braininitiative.nih.gov/funding/.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum, including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research.In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process should be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult companion FOAs listed above.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high-value informatics research resources to serve current and emerging needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCIs Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on supporting activities necessary for improved user experience and availability of existing, widely-adopted informatics tools and resources.This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justifications for why the research resource should be maintained and how it has benefited and will continue to benefit the cancer research field.In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and/or deep engagement between the resource and the targeted research community should be described.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as the initial development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field.

This FOA requests research proposals to support collaborative investigative teams or individual scientists who propose unusually innovative research projects, which, if successful, would have a major impact in understanding the biology of Down syndrome and the development of new treatments for health conditions experienced by individuals with Down syndrome.  To be considered transformative, projects must have the potential to create or overturn fundamental scientific paradigms through novel approaches, transform the way research is conducted through the development of novel tools or technologies, or lead to major improvements in health through the development of highly innovative therapies, diagnostic tools, or preventive strategies. Consistent with this focus, Transformative Research Award applications should reflect ideas substantially different from mainstream concepts.

The Orphan Disease Center works with closely with community organizations, the biotech community, and researchers to improve therapeutic treatment options for those afflicted with orphan diseases. Oftentimes genetic, orphan diseases are conditions that affect fewer than two hundred thousand individuals nationwide. Due to their relative rarity, research and funding for these conditions is largely unmet. In support of this mission, the center has partnered with the LouLou Foundation, a pioneer in CDKL5 research, and is accepting applications for the CDKL5 Program of Excellence Pilot Grant Program. Through the program, grants of up to $150,000 will be awarded in support of research focused on treatments for CDKL5 Deficiency Disorder. Those with CDD suffer from treatment-resistant seizures, severe cognitive and motor disability, as well as sensory problems. Because there are many knowledge gaps in CDKL5 research, the foundation is interested in any basic research with the potential to contribute to future treatment options. Priority areas established by the foundation include innovative therapeutic approaches for CDD, systems biology and computational modeling approaches, novel applications of functional techniques, and discovery and validation of CDKL5 biomarkers.

Through the TRDRP Postdoctoral Fellowship Award program, three-year grants of up to $180,000 will be awarded in support of postdoctoral researchers training under a designated mentor in one or more of the following research areas: cancer prevention, treatment, and/or biology.

This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. Furthermore, all research projects must be focused upon knowledge of human biology with a translational human endpoint proposed. All P20 grants must include a minimum of two well-developed translational research projects, as well as contribute significantly to the development of specialized shared resources core facilities, improved research model systems, and collaborative research activities with other institutions, P20 awardees, and/or current SPORE grantees

This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.

This Funding Opportunity Announcement (FOA) invites cooperative agreement applications that will contribute to a higher resolution understanding of the physical and functional organization of the human islet tissue environment by describing the composition (cellular and molecular) and function of important components of the pancreatic islet and peri-islet tissue architecture, the cell-cell relationships and means of communications used by cell types and cell subtypes within the pancreatic tissue ecosystem, and/or the contribution of adjacent (including acinar, ductal, lymphatic) and neighboring (intestinal, mesenteric and adipose) tissues to islet cell function and dysfunction. Successful projects will integrate the Human Pancreas Analysis Consortium (HPAC), that will consist of the research teams funded in response to this FOA with the Human Pancreas Analysis Program (HPAP), a resource-generation program that was funded in 2016 in response to RFA-DK-15-027. HPAC will become the fifth consortium of the Human Islet Research Network (HIRN, https://hirnetwork.org/ ). HIRN's overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This FOA will only support studies with a primary focus on increasing our understanding of human tissue structure and function, and human disease biology (as opposed to rodent or other animal models). This FOA is not intended to support the conduct of a clinical trial.

This Funding Opportunity Announcement (FOA) requests applications to explore human pancreatic tissues for the discovery of early biomarkers of T1D pathogenesis, the description of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the development of clinical diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is to better define and detect the mechanisms of beta cell stress and destruction central to the development of T1D in humans, with the long-term goal of detecting beta cell destruction and protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and of preventing the progression to autoimmunity. The CBDS is part of a collaborative research framework, the Human Islet Research Network (HIRN, https://hirnetwork.org), whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This FOA will only support studies with a primary focus on increasing our understanding of human disease biology (as opposed to rodent or other animal models). This FOA will not accept applications proposing a clinical trial.

This Funding Opportunity Announcement (FOA) invites cooperative agreement applications that will contribute to a higher resolution understanding of the physical and functional organization of the human islet tissue environment by describing the composition (cellular and molecular) and function of important components of the pancreatic islet and peri-islet tissue architecture, the cell-cell relationships and means of communications used by cell types and cell subtypes within the pancreatic tissue ecosystem, and/or the contribution of adjacent (including acinar, ductal, lymphatic) and neighboring (intestinal, mesenteric and adipose) tissues to islet cell function and dysfunction. Successful projects will integrate the Human Pancreas Analysis Consortium (HPAC), that will consist of the research teams funded in response to this FOA with the Human Pancreas Analysis Program (HPAP), a resource-generation program that was funded in 2016 in response to RFA-DK-15-027. HPAC will become the fifth consortium of the Human Islet Research Network (HIRN, https://hirnetwork.org/ ). HIRN's overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This FOA will only support studies with a primary focus on increasing our understanding of human tissue structure and function, and human disease biology (as opposed to rodent or other animal models). This FOA will not accept applications proposing a clinical trial.

The Chan Zuckerberg Initiative is inviting applications to join the CZI Neurodegeneration Challenge Network. The goal of this interdisciplinary collaborative initiative is to bring together forward-thinking scientists to work on the challenge of neurodegenerative disorders, with a focus on basic mechanisms in the context of human disease biology.

In celebrating its 350th anniversary, Merck KGaA, Darmstadt, Germany offers a series of research grants to stimulate innovative research in challenging areas of future importance. Merck KGaA, Darmstadt, Germany intends to provide several research grants of up to EUR 350,000 per year for 3 years in various research areas with the option of extension or expansion. Grants are offered for research in the following areas: Healthy Lives / Drug Discovery: Challenge 1: What is the next game-changing molecule or technology to help cure cancer or autoimmune disease? Life Reimagined / Synthetic Biology: Challenge 1: What is the next generation production technology for biologics? Challenge 2: Can you revolutionize microbiome research? Materials & Solutions: Challenge 1: Can you develop a new generation of intelligent materials? Challenge 2: Can you develop advances in characterization, control and surface chemistry? Challenge 3: Can you develop better atomic layer processes - from modelling to materials? Digitalization / Computing: Challenge 1: How can in-silico research benefit from deep learning or quantum computing?

The purpose of this funding opportunity announcement (FOA) is to promote initial establishment of basic science-clinical collaborations by providing small grants to teams of basic scientists, physician scientists, and/or clinicians. These interdisciplinary teams may include but are not limited to the following: developmental biologists, cell biologists, geneticists, genomicists, physician scientists including individuals with DVM/VMD degrees, clinicians, epidemiologists, biostatisticians, and/or bioinformaticists. Applications must include at least one scientist with expertise from the basic science side of the spectrum as well as one from the clinical side. The multiple PD/PI model is strongly encouraged but not required. The goal is to facilitate the gathering of preliminary data to support future, larger research grant applications that will combine expertise and integrate basic, translational, and/or clinical approaches to understanding the developmental biology, genetics, and/or environmental basis of structural birth defects.

This Funding Opportunity Announcement (FOA) invites new and renewal applications to participate in the Consortium on Modeling Autoimmune Interactions (CMAI). CMAI is a component of the Human Islet Research Network (HIRN) that is focused on developing robust systems to measure and model the biology of human type 1 diabetes. Projects will explore and validate research models designed to advance pre-clinical scientific discovery, mechanistic dissection of disease processes, and testing of potential interventions for T1D. 

The DeGregorio Family Foundation for Gastric and Esophageal Cancer seeks to promote and facilitate collaborative research on the pathogenesis, early diagnosis, and treatment of upper gastrointestinal malignancies. To that end, the foundation has issued a Request for Proposals for its ninth annual funding opportunity for gastroesophageal malignancies. Through the RFP, grants of up to $250,000 will be awarded in support of innovative, high-quality translational and bench research that improves the understanding of the biology of these diseases, identification of potential novel therapeutic targets, and/or the development and evaluation of novel biomarkers for early diagnosis and treatment. Pre-clinical research, basic mechanistic studies, genomic/epigenomic studies, and epidemiologic studies are eligible for support.